CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 89 filers reported holding CARDIFF ONCOLOGY INC in Q4 2021. The put-call ratio across all filers is 2.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $402,922 | +190.0% | 289,872 | +206.7% | 0.00% | – |
| Q2 2023 | $138,921 | -66.3% | 94,504 | -62.2% | 0.00% | – |
| Q1 2023 | $412,175 | +49.0% | 249,803 | +26.4% | 0.00% | – |
| Q4 2022 | $276,613 | -28.3% | 197,581 | -21.1% | 0.00% | – |
| Q3 2022 | $386,000 | -50.9% | 250,468 | -29.9% | 0.00% | – |
| Q2 2022 | $786,000 | +88.0% | 357,097 | +111.7% | 0.00% | – |
| Q1 2022 | $418,000 | -90.5% | 168,656 | -76.8% | 0.00% | – |
| Q4 2021 | $4,380,000 | +51.7% | 728,524 | +68.1% | 0.00% | – |
| Q3 2021 | $2,887,000 | +9.2% | 433,336 | +9.0% | 0.00% | – |
| Q2 2021 | $2,644,000 | -59.1% | 397,461 | -43.1% | 0.00% | -100.0% |
| Q1 2021 | $6,468,000 | -73.8% | 698,549 | -49.0% | 0.00% | -66.7% |
| Q4 2020 | $24,642,000 | +378.6% | 1,369,802 | +277.5% | 0.00% | +200.0% |
| Q3 2020 | $5,149,000 | – | 362,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |